A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With RAEB-1 AND RAEB-2 Myelodysplastic Syndrome (MDS) and AML With Trisomy 8
Phase of Trial: Phase I
Latest Information Update: 10 Jan 2019
At a glance
- Drugs Rigosertib (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 19 Jul 2012 Additional lead trial investigator (Neal S Young) identified as reported by ClinicalTrials.gov.
- 07 Jun 2012 Additional lead trial investigator identified as reported by ClinicalTrials.gov.